Citigroup’s 2seventy bio TSVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-34,664
Closed -$171K 5909
2025
Q1
$171K Sell
34,664
-3,091
-8% -$9.82K ﹤0.01% 4286
2024
Q4
$111K Buy
37,755
+1,677
+5% +$6.88K ﹤0.01% 4783
2024
Q3
$170K Buy
36,078
+24,650
+216% +$111K ﹤0.01% 4450
2024
Q2
$44K Buy
11,428
+2,757
+32% +$12.4K ﹤0.01% 4665
2024
Q1
$46.4K Buy
8,671
+1,328
+18% +$6.25K ﹤0.01% 4661
2023
Q4
$31.4K Buy
7,343
+3,800
+107% +$11.7K ﹤0.01% 4773
2023
Q3
$13.9K Sell
3,543
-81,907
-96% -$537K ﹤0.01% 4476
2023
Q2
$865K Sell
85,450
-177,526
-68% -$1.88M ﹤0.01% 2955
2023
Q1
$2.68M Buy
262,976
+198,403
+307% +$2.27M ﹤0.01% 1826
2022
Q4
$605K Sell
64,573
-55,091
-46% -$777K ﹤0.01% 3025
2022
Q3
$1.74M Buy
119,664
+29,661
+33% +$440K ﹤0.01% 2255
2022
Q2
$1.19M Buy
90,003
+52,543
+140% +$716K ﹤0.01% 2516
2022
Q1
$639K Sell
37,460
-105,295
-74% -$1.79M ﹤0.01% 3334
2021
Q4
$3.66M Buy
+142,755
New +$4.45M ﹤0.01% 2095

Other funds holding TSVT

Citigroup's TSVT Position: Q2 2025 in Review

Citigroup sold out of 2seventy bio (TSVT) in Q2 2025, closing a stake of 34,664 shares — an estimated $171K sold.

Citigroup first reported a position in TSVT in Q4 2021 and held it in 14 quarters. The position peaked at $3.66M in Q4 2021. 2 funds tracked by Wall St. Rank hold TSVT as of Q2 2025.

  • Citigroup reported no remaining 2seventy bio position as of Q2 2025 after selling out during the quarter.
  • Citigroup sold 34,664 2seventy bio shares in Q2 2025, an estimated $171K.
  • Citigroup first reported a position in 2seventy bio in Q4 2021 and held it in 14 quarters.
  • Citigroup's 2seventy bio position peaked at $3.66M in Q4 2021.
  • 2 funds tracked by Wall St. Rank held 2seventy bio as of Q2 2025.

Based on Citigroup's 13F filing for Q2 2025, filed 11 Aug 2025.